Subscribe to Journal
Get full journal access for 1 year
only $102.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016; 30: 1648–1671.
Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30: 1044–1054.
Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol 2016; 34: 2333–2340.
Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol 2014; 89: 732–742.
Cortes JE, Kim D-W, Pinilla-Ibarz J, Le Coutre P, Paquette R, Chuah C et al. Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial. Blood 2014; 124: 3135.
Gambacorti-Passerini C, Cortes JE, Lipton JH, Dmoszynska A, Wong RS, Rossiev V et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol 2014; 89: 947–953.
Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128–2137.
Seferian A, Chaumais MC, Savale L, Günther S, Tubert-Bitter P, Humbert M et al. Drugs induced pulmonary arterial hypertension. Presse Med 2013; 42 (9 Pt 2): e303–e310.
The authors thank Nathalie Ross, Science and Medical Writer, funded by Novartis Pharmaceuticals for contributing to the writing and editing of this Correspondence. Novartis had no influence on the content of this document.
Dr Christian Constance has received honorarium and support for clinical trials from Astra, Bayer, Boehringer Ingelheim, Novartis and Pfizer. Dr David Langleben has received honoraria and support for clinical trials from Actelio, Bayer, Eiger Biophamaceuticals, Ikaria, Northern Therapeutics, Novartis and United Therapeutics. He has served on advisory boards for Actelion, Bayer, Ikaria, Northern Therapeutics, Novartis, UCB Celltech and United Therapeutics. The remaining authors declare no conflict of interest.
About this article
Cite this article
Constance, C., Trudeau, L., Jolicoeur, E. et al. Cardiologist’s perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 31, 771–772 (2017). https://doi.org/10.1038/leu.2016.336
Chronic Myeloid Leukemia: What Is the Best Strategy to Start and Monitor Treatment Outside Academic Centers?
Current Oncology Reports (2018)
Japanese Journal of Thrombosis and Hemostasis (2018)